PD-1/PD-L1 interaction(PD-1/PD-L1 相互作用)
Programmed death-1 (PD-1) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1) or PD-L2. When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self tolerance.
Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1.
In addition to enhancing immunologic responses to chronic antigens, blockade of the PD-1/PD-L1 pathway has also been shown to enhance responses to vaccination, including therapeutic vaccination in the context of chronic infection.
Products for PD-1/PD-L1 interaction
- Cat.No. 产品名称 Information
- GC31878 PD1-IN-2 PD1-IN-2 是一种 PD1 信号通路抑制剂,可作为免疫调节剂。
-
GC31753
BMS-1166 (PD-1/PD-L1-IN1)
A PD-1/PD-L1 interaction inhibitor
- GC31719 Avelumab (Anti-Human PD-L1, Human Antibody) Avelumab (anti-PD-L1) (Bavencio, MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.
- GC19225 PD-1-IN-1 (CA-170) PD-1-IN-1 (CA-170) 是一种口服给药的 VISTA 和 PD-L1 双重抑制剂。
- GC19131 Tomivosertib A potent inhibitor of MNK1 and MNK2
- GC16258 PD-1/PD-L1 Inhibitor 3 A PD-1/PD-L1 interaction inhibitor
- GC15142 PD-1/PD-L1 inhibitor 1 (BMS-1) A PD-1/PD-L1 interaction inhibitor
- GC16762 PD-1/PD-L1 inhibitor 2 A PD-1/PD-L1 interaction inhibitor
- GC10469 Sulfamethoxypyridazine A sulfonamide antibiotic